|
US FDA accepts regulatory submissions for review of tafamidis to treat transthyretin amyloid cardiomyopathy
|
14 January 2019 |
|
Pfizer initiates phase 2b/3 clinical trial for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with moderate to severe alopecia areata
|
05 January 2019 |
|
Pfizer receives positive CHMP opinion for oncology biosimilar, ZIRABEV™ (bevacizumab)
|
14 December 2018 |
|
Pfizer reaches a global agreement with AbbVie
|
04 December 2018 |
|
Pfizer announces Executive Leadership Team
|
09 October 2018 |
|
Pfizer to award more than $3 million in grants to further breast cancer research
|
04 October 2018 |
|
Pfizer terminates domagrozumab (PF-06252616) clinical studies for the treatment of Duchenne muscular dystrophy
|
05 September 2018 |
|
Pfizer and Astellas amend clinical research protocols for two phase 3 trials of enzalutamide in patients with hormone-sensitive prostate cancer
|
29 August 2018 |
|
Pfizer initiates pivotal Phase 3 program for investigational hemophilia B gene therapy
|
16 July 2018 |
|
Pfizer to organize for future growth
|
11 July 2018 |
|
Pfizer announces extension of Zithromax® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness
|
14 June 2018 |
|
Pfizer to expand venture investing with $600 million commitment to Pfizer Ventures
|
06 June 2018 |
|
The Pfizer Foundation announces $5 million in grants to support women and families
|
31 May 2018 |
|
Pfizer begins a Phase 1/2 study to evaluate respiratory syncytial virus (RSV) vaccine
|
22 May 2018 |
|
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy
|
23 April 2018 |
|
Pfizer and Allogene Therapeutics enter into asset contribution agreement for Pfizer's allogeneic CAR T immuno-oncology portfolio
|
03 April 2018 |
|
Pfizer receives Breakthrough Therapy designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis
|
14 February 2018 |
|
Pfizer announces positive top-line results for potential biosimilar to Rituxan® / MabThera®
|
25 January 2018 |
|
FDA approves new Pfizer biosimilar
|
15 December 2017 |
|
Pfizer enters into agreement to develop and commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific region
|
01 December 2017 |